The article summarizes the characteristics of dual and triple GLP-1 targeted drugs in the treatment of obesity—which yield more benefits and less toxic side effects—and provides a reference for making full use of multi-target methods to treat other diseases in the future. This evidence concerns the gene GCG and obesity disorder.